epithalamin is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-06-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
The peptide emerged from research carried out in Saint Petersburg from the late 1980s onward, where investigators searched for shorter active fragments of a pineal preparation known as epithalamin. The name epitalon was chosen to reflect that parent extract. Early reports described effects on neuroendocrine markers and on the lifespan of laboratory animals. Much of that work appeared in Russian-language journals, with English translations following later, which affects how readily the original protocols can be assessed by outside groups.
Published studies on epitalon are dominated by a small number of research groups, and independent replication in other laboratories remains limited. Proposed mechanisms include activation of telomerase and modulation of melatonin rhythms, but the evidence for either rests mainly on cell cultures and animal models. Whether the peptide produces comparable effects in humans is an open question, and the absence of large controlled trials means the literature is best read as exploratory rather than settled.
Freeze-dried epitalon is normally kept at minus twenty degrees Celsius in a sealed, desiccated container, protected from light. Short excursions at ambient temperature during shipping are generally tolerated, but repeated warming and cooling cycles encourage moisture uptake, which shortens shelf life. Once dissolved, the peptide is far less stable than the solid: aqueous solutions are subject to hydrolysis and to deamidation at the aspartate and glutamate residues. Working solutions are therefore held refrigerated and used within days, and repeated freezing and thawing of the same vial is best avoided.
Identity and purity are checked by reversed-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, where the peptide bond absorbs. Mass spectrometry confirms the expected mass and reveals whether truncation products or adducts are present. Acid hydrolysis followed by amino acid analysis gives the residue ratio, which should approximate one alanine, one glutamate, one aspartate and one glycine. Counter-ions such as acetate or trifluoroacetate remain in the dried product and lower net peptide content, so a stated purity figure on a label does not by itself describe how much peptide a vial holds.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C14H22N4O9 | Derived from the four-residue sequence |
| Molar mass | About 390.35 g/mol | Free peptide, counter-ion not included |
| Appearance | White to off-white powder | Lyophilised solid from aqueous solution |
| Water solubility | Freely soluble | Short, polar peptide chain |
| Common synonyms | AEDG; epithalone | Catalogues use the names interchangeably |
Epitalon is the common name for a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, usually abbreviated AEDG. All four residues are proteinogenic amino acids, and the free peptide has a calculated mass near 390 grams per mole. Because the chain is short and carries no modifications, it is assembled readily by solid-phase synthesis and is distributed mainly as a freeze-dried solid for laboratory work. Catalogue listings use the spellings epitalon, epithalone, and simply AEDG, and the three refer to the same sequence.
The compound is generally presented as a synthetic fragment of epithalamin, a pineal gland extract investigated in the former Soviet Union from the 1970s onward. Vladimir Khavinson and colleagues in Saint Petersburg developed short peptides modelled on such extracts, and epitalon became the most widely cited of those sequences. Most primary reports appeared in Russian-language journals or in proceedings with limited international circulation. Independent replication in laboratories outside that network remains sparse, and much repeated secondary material traces back to a small number of originating groups.
Laboratory work has examined effects on telomerase activity in cultured cells, on melatonin rhythms in animals, and on markers of oxidative stress. Some experiments report measurable changes while others show none, and the reported findings rest largely on small studies. The absence of large independent trials means the generality of these results is unresolved rather than settled. Review articles occasionally apply the label geroprotector, a term that reflects a research hypothesis about ageing rather than an established clinical finding.
Animal and clinical reports appear mainly in Russian-language journals from the 1990s and 2000s, covering endpoints such as melatonin rhythm, lifespan in aged rodents, and retinal function. Many of these papers involve small groups, lack blinding or placebo comparison, and are difficult to retrieve through indexed databases. Review articles published in English generally summarise the claims without reanalysing the underlying data. Because no large randomised trial exists, the clinical importance of these reported effects stays unresolved and is properly described as an open question.
No national medicines regulator has approved epitalon as a therapeutic product. It is generally distributed as a research chemical, and in some jurisdictions selling peptides for human consumption without approval is restricted or prohibited. Certificates of analysis accompanying commercial material vary in which tests are performed, and independent verification of identity and purity is uncommon. Statements about anti-ageing or disease-prevention benefits on vendor pages are marketing claims rather than regulatory findings, a distinction that shapes how the compound is discussed in scientific and popular sources alike.
Epitalon is a synthetic tetrapeptide whose four residues are alanine, glutamate, aspartate and glycine, commonly abbreviated AEDG. Its molecular formula is C14H22N4O9 and its monoisotopic mass is near 390.35 daltons. The peptide carries two acidic side chains, so it is neutral to negatively charged in most aqueous buffers. Published reference summaries usually list it under both spellings, epitalon and epithalon, and treat the two names as the same material.
The compound is generally described as a synthetic analogue of a fragment isolated from a pineal gland extract. Researchers associated with the Saint Petersburg Institute of Bioregulation and Gerontology introduced it during the 1980s and 1990s while studying short peptides from animal tissue. The original extract, called epithalamin, is a heterogeneous mixture, whereas epitalon is a single defined sequence. That distinction matters because findings reported for the extract are not automatically findings about the pure tetrapeptide, and claims about broader biological effects remain a separate question from the chemical identity described here.
Residue composition is the property that most cleanly separates verified material from mislabelled samples. Alanine, glutamate, aspartate and glycine appear in that order from the N-terminus, and the two acidic residues sit in the middle of the chain. Because the peptide is short, it can be produced by solid-phase synthesis and characterised by mass spectrometry without ambiguity. Any reported sample whose measured mass departs substantially from 390 daltons is a different compound or a degraded mixture rather than epitalon.
=== Temporal lobe === Functions of the temporal lobe are related to many of the deficits observed in individuals with ASDs, such as receptive language, social cognition, joint attention, action observation, and empathy. The temporal lobe also contains the superior temporal sulcus and the fusiform face area, which may mediate facial processing. It has been argued that dysfunction in the superior temporal sulcus underlies the social deficits that characterize autism. Compared to neurotypical individuals, one study found that individuals with high-functioning autism had reduced activity in the fusiform face area when viewing pictures of faces.
The term proofreading is used in genetics to refer to the error-correcting processes, first proposed by John Hopfield and Jacques Ninio, involved in DNA replication, immune system specificity, and enzyme-substrate recognition among many other processes that require enhanced specificity. The kinetic proofreading mechanisms of Hopfield and Ninio are non-equilibrium active processes that consume ATP to enhance specificity of various biochemical reactions. In bacteria, all three DNA polymerases (I, II and III) have the ability to proofread, using 3' → 5' exonuclease activity. When an incorrect base pair is recognized, DNA polymerase reverses its direction by one base pair of DNA and excises the mismatched base. Following base excision, the polymerase can re-insert the correct base and replication can continue. In eukaryotes, only the polymerases that deal with the elongation (delta and epsilon) have proofreading ability (3' → 5' exonuclease activity).Proofreading also occurs in mRNA translation for protein synthesis. In this case, one mechanism is the release of any incorrect aminoacyl-tRNA before peptide bond formation. The extent of proofreading in DNA replication determines the mutation rate, and is different in different species. For example, loss of proofreading due to mutations in the DNA polymerase epsilon gene results in a hyper-mutated genotype with >100 mutations per million bases of DNA in human colorectal cancers.
=== Act 1 === W.P. Inman, a Confederate soldier wounded at the Battle of Petersburg, decides to desert from the Confederate Army and return home to Ada Monroe, his beloved who lives at Black Cove Farm, in North Carolina. Inman is aware of the Home Guard, which hunts down deserters from the Confederate Army. The leader of the local Home Guard is Teague, who resorts to such practices as burying deserters alive. On his journey home, Inman meets Solomon Veasey, whom he stops from committing murder. Meanwhile, Ada, once privileged, leads a life of material desperation. Ada meets Ruby, a mountain woman who teaches Ada about hunting and surviving. Inman encounters Veasey again, near a river whilst fleeing the Home Guard, and bargains with him for passage across the river. However, their vessel capsizes and the two drift down the river. The next morning, Lila and her three sisters see Inman and Veasey. Lila's husband drugs the two men before giving them up to the Home Guard. Inman and Veasey are put on a chain gang of deserters. Back at Black Cove Farm, Ruby finds her estranged father, Stobrod, a fiddler. Strobod is trying to steal food. Ruby wants nothing to do with her father, although he asserts that he has reformed his ways. Teague approaches, and Ruby hides her father. She later orders her father to stay away from her. Inman starts an insurrection among the chain gang. The guards shoot the entire chain gang, with a wounded Inman as the only survivor, chained to six dead prisoners. He relives the day he bid Ada farewell, when he thought that the war would last but six months.
Sources: en.wikipedia.org
== Career == In December 1986, Cameron joined the Department of Chemical Engineering at the University of Wisconsin—Madison, as an assistant professor and advanced to full professor. The focus of his research was metabolic engineering (a field now more commonly known as synthetic biology) and industrial microbiology. One of his first projects was the engineering of the microbial pathway for 1,3-propanediol in Escherichia coli. This work was an early step in a process that was eventually commercialized by DuPont and Tate & Lyle. He is also the inventor of a process for the microbial production of 3-hydroxypropionic acid, which provides a bio-based route to industrial chemicals such as acrylic acid. In 1996 he did a sabbatical at the ETH Zurich (Switzerland) in the laboratory of James (Jay) E. Bailey. In 1998 he took a leave of absence to start the Biotechnology Development Center (BioTDC) at Cargill, Inc. in Minneapolis. In 2000 he officially left the University of Wisconsin. Cameron was at Cargill, Inc. from 1998 to 2006, where he was Director of Biotechnology and chief scientist. While at Cargill he worked closely with NatureWorks on the development of a low-pH process for lactic acid as a feedstock for polylactic acid. He and his team also worked with Cargill Ventures on deal-sourcing and due-diligence. In June 2006, Cameron moved from Cargill to join the newly formed Silicon Valley venture capital firm, Khosla Ventures, as chief scientific officer. In 2008, Cameron returned to the Midwest to help Piper Jaffray build and grow its clean tech investment business.
District Court judicial nominees who Kennedy believed were not qualified: Jeff Mateer, Brett Talley, and Matthew S. Petersen. The White House withdrew all three nominations. On December 13, 2017, during Petersen's confirmation hearing before the Senate Judiciary Committee, Kennedy asked Petersen about basic legal procedure, whether he knew what the Daubert standard was and what a motion in limine was. Petersen struggled to answer. Kennedy also voted against the nomination of Gregory G. Katsas to the D.C. Circuit, but Katsas was confirmed. On April 7, 2017, Kennedy voted to confirm Neil Gorsuch to the United States Supreme Court. Kennedy participated in Gorsuch's confirmation as a member of the Judiciary Committee. During the confirmation process, Kennedy said, “Neil Gorsuch is obviously very well-qualified based on his education and background, but I want to know what’s in his heart. I want to know what he thinks about past Supreme Court decisions and how the justices reached those decisions. I want to know whether he thinks personal preferences have a role in the judicial decision-making. I want to know if he knows the name of the person who cleans his office. Also, I'm rather fond of the U.S. Constitution, and I want to make sure he is, too." On October 6, 2018, Kennedy voted to confirm Brett Kavanaugh to the Supreme Court. As a member of the Judiciary Committee, Kennedy participated in Kavanaugh's contentious nomination hearing after Christine Blasey Ford accused Kavanaugh of sexual assault.
=== Newborn screening === On May 9, 2014, the UK National Screening Committee (UK NSC) announced its recommendation to screen every newborn baby in the UK for four further genetic disorders as part of its NHS Newborn Blood Spot Screening programme, including maple syrup urine disease. The disease is estimated to affect 1 out of 185,000 infants worldwide and its frequency increases with certain heritages. Newborn screening for maple syrup urine disease involves analyzing the blood of 1–2 day-old newborns through tandem mass spectrometry. The blood concentration of leucine and isoleucine is measured relative to other amino acids to determine if the newborn has a high level of branched-chain amino acids. Once the newborn is 2–3 days old the blood concentration of branched-chain amino acids like leucine is greater than 1000 μmol/L and alternative screening methods are used. Instead, the newborn's urine is analyzed for levels of branched-chain alpha-hydroxyacids and alpha-ketoacids. Other diagnostic methods include additional laboratory studies which include gas and liquid chromatography, BCKAD (branched-chain alpha-keto acid dehydrogenase) enzyme activity, dinitrophenylhydrazine (DNPH) test, and molecular testing. Gas chromatography-mass spectrometry, urine test strips and the DNPH test can detect urinary organic acid that supports the diagnosis of MSUD. Branched-chain-ketoacids can be detected by the DNPH test, where the DNPH reagent and urine get mixed equally and are observed for ten minutes to see color and precipitation changes.
Sources: en.wikipedia.org
It is a synthetic tetrapeptide built from alanine, glutamate, aspartate and glycine. The four residues are joined by standard peptide bonds, giving a linear chain rather than a branched structure.
The name derives from epithalamin, a pineal gland extract studied in the former Soviet Union. Researchers proposed that short fragments of that extract carried the biological activity of interest.
No major regulatory agency has approved it as a medicine. It is handled as a research chemical, and products sold under this name are not standardised drugs with defined clinical labelling.
The solid is kept cold, dry and dark, typically at minus twenty degrees Celsius, in a sealed container with desiccant. Dissolved material is kept refrigerated and used promptly. Freezing and thawing a solution repeatedly is avoided because it accelerates degradation.